153 related articles for article (PubMed ID: 20452658)
1. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
Miller BE; Blessing JA; Stehman FB; Shahin MS; Yamada SD; Secord AA; Warshal DP; Abulafia O; Richards WE; Van Le L
Gynecol Oncol; 2010 Aug; 118(2):139-44. PubMed ID: 20452658
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
Hensley ML; Blessing JA; Mannel R; Rose PG
Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
[TBL] [Abstract][Full Text] [Related]
4. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
[TBL] [Abstract][Full Text] [Related]
9. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW
World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Powell MA; Filiaci VL; Rose PG; Mannel RS; Hanjani P; Degeest K; Miller BE; Susumu N; Ueland FR
J Clin Oncol; 2010 Jun; 28(16):2727-31. PubMed ID: 20421537
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Boukovinas I; Androulakis N; Kentepozidis N; Polyzos A; Papakotoulas P; Ziras N; Kotsakis A; Vardakis N; Karampeazis A; Markos V; Kostakopoulos A; Constantinides CA; Samonis G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2012 Feb; 69(2):351-6. PubMed ID: 21748359
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
Oncologist; 2012; 17(3):321. PubMed ID: 22363068
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study.
Curtin JP; Blessing JA; Soper JT; DeGeest K
Gynecol Oncol; 2001 Nov; 83(2):268-70. PubMed ID: 11606082
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Spiridonidis CH; Laufman LR; Carman L; Moore T; Blair S; Jones J; George C; Patel T; Roach R; Rupert R; Zangmeister J; Colborn D; Kuebler JP
Ann Oncol; 2001 Jan; 12(1):89-94. PubMed ID: 11249055
[TBL] [Abstract][Full Text] [Related]
18. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Boukovinas I; Androulakis N; Vamvakas L; Papakotoulas P; Ziras N; Polyzos A; Kalykaki A; Kotsakis A; Xenidis N; Gioulmbasanis I; Mavroudis D; Georgoulias V
Ann Oncol; 2006 Nov; 17(11):1687-92. PubMed ID: 16968872
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Mekhail T; Hutson TE; Elson P; Budd GT; Srkalovic G; Olencki T; Peereboom D; Pelley R; Bukowski RM
Cancer; 2003 Jan; 97(1):170-8. PubMed ID: 12491518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
